Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy
Opioids are mainly used to treat both acute and chronic pain. Several opioids are
metabolized to some extent by CYP2D6 (codeine, tramadol, hydrocodone, oxycodone, and …
metabolized to some extent by CYP2D6 (codeine, tramadol, hydrocodone, oxycodone, and …
Trends in tramadol: pharmacology, metabolism, and misuse
Tramadol is a unique analgesic medication, available in variety of formulations, with both
monoaminergic reuptake inhibitory and opioid receptor agonist activity increasingly …
monoaminergic reuptake inhibitory and opioid receptor agonist activity increasingly …
Worldwide distribution of cytochrome P450 alleles: a meta‐analysis of population‐scale sequencing projects
Y Zhou, M Ingelman‐Sundberg… - Clinical Pharmacology …, 2017 - Wiley Online Library
Genetic polymorphisms in cytochrome P450 (CYP) genes can result in altered metabolic
activity toward a plethora of clinically important medications. Thus, single nucleotide variants …
activity toward a plethora of clinically important medications. Thus, single nucleotide variants …
[HTML][HTML] Basic review of the cytochrome p450 system
AM McDonnell, CH Dang - Journal of the advanced practitioner in …, 2013 - ncbi.nlm.nih.gov
Basic Review of the Cytochrome P450 System - PMC Back to Top Skip to main content NIH
NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation …
NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation …
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype
KR Crews, A Gaedigk… - Clinical …, 2012 - Wiley Online Library
Codeine is bioactivated to morphine, a strong opioid agonist, by the hepatic cytochrome
P450 2D6 (CYP2D6); hence, the efficacy and safety of codeine as an analgesic are …
P450 2D6 (CYP2D6); hence, the efficacy and safety of codeine as an analgesic are …
[HTML][HTML] CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial
Purpose CYP2D6 bioactivates codeine and tramadol, with intermediate and poor
metabolizers (IMs and PMs) expected to have impaired analgesia. This pragmatic proof-of …
metabolizers (IMs and PMs) expected to have impaired analgesia. This pragmatic proof-of …
Review of opioid pharmacogenetics and considerations for pain management
A Owusu Obeng, I Hamadeh… - … : The Journal of Human …, 2017 - Wiley Online Library
Opioid analgesics are the standards of care for the treatment of moderate to severe
nociceptive pain, particularly in the setting of cancer and surgery. Their analgesic properties …
nociceptive pain, particularly in the setting of cancer and surgery. Their analgesic properties …
Non-analgesic effects of opioids: opioid-induced respiratory depression
M Boom, M Niesters, E Sarton, L Aarts… - Current …, 2012 - ingentaconnect.com
Opioids induce respiratory depression via activation of μ-opioid receptors at specific sites in
the central nervous system including the pre-Bötzinger complex, a respiratory rhythm …
the central nervous system including the pre-Bötzinger complex, a respiratory rhythm …
[HTML][HTML] A review on tramadol toxicity: mechanism of action, clinical presentation, and treatment
Aims As an analgesic that acts upon the central nervous system (CNS), tramadol has gained
popularity in treating moderate to severe pain. Recently, it has been increasingly reported as …
popularity in treating moderate to severe pain. Recently, it has been increasingly reported as …
Genetic polymorphism and toxicology—with emphasis on cytochrome p450
I Johansson, M Ingelman-Sundberg - Toxicological sciences, 2011 - academic.oup.com
Individual susceptibility to environmental, chemical, and drug toxicity is to some extent
determined by polymorphism in drug-metabolizing enzymes, in particular the cytochromes …
determined by polymorphism in drug-metabolizing enzymes, in particular the cytochromes …